Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least […]

Melanotan 1 (Melanotan I) is a synthetic, alpha-melanocyte-stimulating hormone (α-MSH) mimicking compound with a product description that focuses on inducing tanning by stimulating melanin production by melanocytes, as well as having the potential for prevention of skin cancer, use in melanoma research, and treatment of erectile dysfunction in men. TANNING PROMOTION: By mimicking the binding […]

Se, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. To reduce excess body weight and maintain weight reduction long term in people aged twelve years of age and older with obesity or […]

Tir is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness,  nerve problems, loss of limbs, and sexual function problems. Mechanism of action: It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, […]

Retatrutide operates through a unique mechanism as a triple agonist, targeting the GIP, GLP-1, and GCG receptors, with a strong emphasis on GIP receptor activation. This receptor interaction leads to a comprehensive approach to metabolic regulation, significantly impacting both glycemic control and weight loss. Below is an overview of the underlying mechanisms: Retatrutide’s primary mechanism involves […]

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least […]